Company News

Share this article:

Abbott opened a nutrition product manufacturing facility in Singapore, in order to meet increasing regional demand for its pediatric products, including Similac, according to company statement. The facility represents the company's largest nutrition investment to date, at $300 million. According to Abbott, the facility will serve up to one million Asian infants and children each year.

 

FDA halted the review of all NDA's received from a Ranbaxy Laboratories plant in India, after discovering falsified data. In a letter to Ranbaxy, CDER director Janet Woodcock said the findings “indicate a pattern and practice of submitting untrue statements of material fact and other wrongful conduct, which raise significant questions regarding the reliability of the data and information contained in applications (pending and approved) that [Ranbaxy] has filed with the agency and which contain data developed at the Ranbaxy Laboratories, Paonta Sahib site.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions